ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial
ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an adjuvanted booster vaccine for SARS-CoV-2, the virus responsible for COVID-19. ACM-001 is the company’s first clinical-stage development programme.
The booster vaccine utilises a spike-protein component from the immune-evasive beta SARS-CoV-2 variant as well as an immunostimulant, CpG 7909, made via the company’s polymer-based delivery technology, ACM Biolabs’ Tunable Platform (ATP).
The trial demonstrated that the vaccine candidate was safe and well-tolerated at the recommended dose level for both intramuscular injection and mucosal delivery. Early immunogenicity data was promising, suggesting that the vaccine initiated a broadly active antibody response targeting all variants including currently circulating omicron strains.
Further data is expected to be published in the coming months.
Madhavan Nallani, PhD, chief executive officer at ACM Biolabs, commented: “This is excellent news for ACM Biolabs as it substantially de-risks our core technology and enables us to progress all our formulations in discovery and development. We have received a lot of interest in our technology from partners who we believe will find the data valuable as we advance projects with them.”
Pierre Vandepapelière, MD PhD, chief medical officer at ACM Biolabs, stated: “These positive phase 1 results provide clinical validation for ATP, our flexible proprietary delivery platform. It means we can move forward with confidence and explore the full potential of the technology in multiple therapeutic areas including vaccines. What excites us the most is the broader neutralisation upon vaccine administration suggests the high quality of antibodies generated by targeting immune cells. On behalf of ACM, I would like to thank all study participants and staff members at the clinical sites.”
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …
Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human …